Overview

To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, randomised, double-blind, placebo-controlled, 4-way cross-over study. At each study visit a standardised treadmill test will be performed to provoke EIA. Before and after the challenge test pulmonary function variables (e.g. forced expiratory volume in one second (FEV1)) will be measured in order to assess the protective effect of the study medication.
Phase:
Phase 2
Details
Lead Sponsor:
MEDA Pharma GmbH & Co. KG
Collaborators:
ClinResearch, GmbH
Sanofi
Treatments:
Cromolyn Sodium
Metaproterenol
Reproterol
Theophylline